Visium, MERFISH, and Slide-seq for Tumor-Immune Interface Mapping: Resolution Tradeoffs, Causal Validation, and Clinical Translation
Resolution and sensitivity tradeoffs between Visium, MERFISH, and Slide-seq for tumor-immune interface mapping, subcellular platforms, causal validation with Perturb-FISH, and clinical translation of spatial transcriptomics.
May 20, 2026
